Picture3.jpg
Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board
March 14, 2023 08:55 ET | Clearmind Medicine Inc.
Professor Kranzler is the Benjamin Rush Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania’s Perelman School of Medicine Tel Aviv, Israel...
Picture3.jpg
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
February 22, 2023 08:00 ET | Clearmind Medicine Inc.
The company submitted three provisional patent applications with the United States Patent and Trademark Office to protect the novel combination compounds with SciSparc's PEA Tel Aviv, Israel /...
Picture3.jpg
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
February 15, 2023 08:30 ET | Clearmind Medicine Inc.
The applications for novel psychedelic-based combinations, developed with SciSparc, are based on monotherapy and novel combinations of SciSparc's Cannamide™ and classical psychedelics Tel Aviv,...
Picture3.jpg
Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv
February 14, 2023 08:30 ET | Clearmind Medicine Inc.
Dr. Adi Zuloff-Shani PhD., Clearmind’s chief executive officer will discuss its Nasdaq IPO with David Huberman, Capital Markets Shareholder at Greenberg Traurig law firm Tel Aviv, Israel /...
Picture3.jpg
Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
February 08, 2023 08:30 ET | Clearmind Medicine Inc.
The conference will stream live on Tuesday, February 28, at 8:30 AM EST Tel Aviv, Israel / Vancouver, Canada, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE:...
Picture3.jpg
Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound
January 31, 2023 09:00 ET | Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on...
Picture3.jpg
Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
January 25, 2023 08:30 ET | Clearmind Medicine Inc.
Isranalytica 2023, the Annual meeting of the Israel Analytical Chemical Society, provided Clearmind with the opportunity to garner visibility for its drug candidate MEAI from attendees at one of the...
Picture3.jpg
Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum
January 19, 2023 09:00 ET | Clearmind Medicine Inc.
The two drug-discovery projects for novel, next generation, innovative, patentable psychedelic compounds, are expected to expand Clearmind’s IP portfolio Tel Aviv, Israel / Vancouver, Canada, Jan. ...
Picture3.jpg
Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
January 17, 2023 09:00 ET | Clearmind Medicine Inc.
The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of substance addiction without interrupting the natural reward...
Picture3.jpg
Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial
January 10, 2023 08:30 ET | Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...